Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2406233 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy.
Prog Cardiovasc Dis
December 2024
Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, United States of America.
American culture encourages overconsumption, fueled by ubiquitous availability and pervasive marketing of ultra-processed foods and other addictive substances. This chronic overindulgence has contributed to rising rates of obesity, type 2 diabetes (T2D), substance abuse, mental health disorders and premature mortality. Glucose-like peptide-1 agonists (GLP-1RAs) affect the brain's reward pathway that mediates addiction to foods and various other substances.
View Article and Find Full Text PDFContemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system.
Obesity (Silver Spring)
December 2024
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Objective: The objective of this study was to describe the prevalence of obesity, obesity-related conditions (ORCs), and antiobesity medication (AOM) eligibility and prescribing practice among eligible patients in a large health care system.
Methods: In this cross-sectional analysis of the multicenter Mass General Brigham health care system (Boston, Massachusetts) spanning 2018 to 2022, adults eligible for AOMs (BMI ≥ 30 kg/m or BMI 27-29.9 kg/m with ≥1 ORC) were identified.
Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review.
Expert Opin Pharmacother
January 2025
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Article Synopsis
- Traditional treatments for obstructive sleep apnea (OSA) mainly focus on methods like continuous positive airway pressure therapy and oral appliances, but they don't tackle the underlying metabolic issues that contribute to the condition.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially created for managing type 2 diabetes, show promise in helping obese patients with OSA by promoting significant weight loss and reducing fat around the airway.
- Emerging research indicates that integrating GLP-1 RAs into standard OSA treatments could improve patient outcomes by addressing both obesity and related health issues, potentially changing the way OSA is managed in the future.
Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle.
bioRxiv
November 2024
Diabetes & Metabolism Research Center, University of Utah, Salt Lake City, UT, USA.
Objective: Glucagon-like peptide 1 receptor agonists (e.g. semaglutide) potently induce weight loss and thereby reducing obesity-related complications.
View Article and Find Full Text PDFThe Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects.
J Clin Med
October 2024
Faculty of Medicine, Wroclaw University of Science and Technology, 51-377 Wroclaw, Poland.
Article Synopsis
- GLP1-RAs are synthetic peptides that mimic the effects of GLP-1, aiding in blood sugar reduction and weight loss, making them useful for managing type 2 diabetes and obesity.
- Recent research suggests that these peptides might also help treat hidradenitis suppurativa (HS), a chronic skin condition linked to metabolic issues like obesity and diabetes.
- A review of 25 studies indicated that GLP1-RAs, particularly liraglutide and semaglutide, can reduce weight and inflammation in HS patients, resulting in better lesion severity and quality of life, though more research is needed to assess long-term effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!